Publications by authors named "Seock-Ah Im"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

20

Total Likes

1

Extended Reach

325

Social Features

4
L
Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer.
Yeon Hee Park, Seock-Ah Im, Kyunghee Park, Ji Wen, Kyung-Hun Lee, Yoon-La Choi, Won-Chul Lee, Ahrum Min, Vinicius Bonato, Seri Park

Genome Med· July 2023

Videos about Article: user

1 1 2

View All Article and Social Media Activity
T
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial.
Shanu Modi, William Jacot, Hiroji Iwata, Yeon Hee Park, Maria Vidal Losada, Seock-Ah Im

Nat Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer.
Sibylle Loibl, Yeon Hee Park, Zhiming Shao, Chiun-Sheng Huang, Carlos Barrios, Seock-Ah Im, Sung-Bae Kim, Joline Lim

N Engl J Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
KEYLYNK-009: Pembrolizumab Plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer and Clinical Benefit From First-Line Pembrolizumab Plus Chemotherapy.
Hope S Rugo, David W Cescon, Mark E Robson, Seock-Ah Im, Florence Dalenc, Young-Hyuck Im, Jaime A Mejia

Clin Cancer Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Redefining HER2 in Breast Cancer: From Conventional Positivity to Low and Ultralow in the New Era of Antibody-Drug Conjugates.
Jiwon Koh, Seock-Ah Im

Cancer Res Treat· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imlunestrant, an oral selective estrogen receptor degrader, in combination with HER2 directed therapy, with or without abemaciclib, in ER-positive, HER2-positive advanced breast cancer: results from the phase 1a/1b EMBER study.
Manali Bhave, Komal L Jhaveri, Peter A Kaufman, Philippe Aftimos, Janine Lombard, Seock-Ah Im, Sung-Bae Kim

Breast Cancer Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Proliferation of Tumor-Related Regulatory T Cells in Circulation Dictates Efficacy of Chemoimmunotherapy in Triple-Negative Breast Cancer.
Seung Hyuck Jeon, Koung Jin Suh, Sungmin Jung, Minwoo Jeon, Ho Cheol Jang, Eui-Soon Kim, Se Hyun Kim, Seock-Ah Im, Min Hwan Kim, Hee-Jun Kim, Milim Kim, Jee Hyun Kim

Clin Cancer Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ribociclib Plus Endocrine Therapy in Hormone Receptor-Positive/ERBB2-Negative Early Breast Cancer: 4-Year Outcomes From the NATALEE Randomized Clinical Trial.
Peter A Fasching, Daniil Stroyakovskiy, Denise A Yardley, Chiun-Sheng Huang, John Crown, Seock-Ah Im

JAMA Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Comparative study on bone mineral density in premenopausal patients with estrogen receptor-positive breast cancer in ASTRRA Study: a 5-year follow-up study.
Eunju Shin, Seung Il Kim, Min-Ho Park, Hyun-Ah Kim, Yongsik Jung, Sung Yong Kim, Seock-Ah Im, Woo Sung Lim, Tae Hyun Kim, Cheol Wan Lim, Bong Kyun Kim, Hee Jeong Kim

Front Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of potential biomarkers with clinical outcomes in metastatic triple-negative breast cancer treated with pembrolizumab or chemotherapy.
Javier Cortes, Oleg Lipatov, Seock-Ah Im, Anthony Goncalves, Keun Seok Lee, Jaime Mejia

NPJ Breast Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal trajectory of menopausal symptoms in premenopausal women throughout adjuvant chemotherapy: a two-stage analytical approach.
Saim Jung, Jaehyun Kim, Sun Hyung Lee, Joon Sung Shin, Won-Hyoung Kim, Tae-Yong Kim, Seock-Ah Im

Support Care Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative study on bone mineral density in premenopausal patients with estrogen receptor-positive breast cancer in ASTRRA Study: a 5-year follow-up study.
Eunju Shin, Seung Il Kim, Min-Ho Park, Hyun-Ah Kim, Yongsik Jung, Sung Yong Kim, Seock-Ah Im, Woo Sung Lim, Tae Hyun Kim, Cheol Wan Lim, Bong Kyun Kim, Hee Jeong Kim

Front Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer Manipulates Adjacent Adipose Tissue to Exploit Fatty Acids via HIF-1α/CCL2/PPARα Axis: A Metabolic Circuit to Support Tumor Progression.
Jeong-Eun Yun, Jieun Seo, Jiwon Koh, Seock-Ah Im, Ki Yong Hong

Adv Sci (Weinh)· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to: Germline and Somatic Mutations in Breast Cancer Treatment Strategies.
Eric Hahnen, Jan Hauke, Karen Gelmon, Frederik Marmé, Corinna Ernst, Seock-Ah Im, Sung-Bae Kim, Toralf Reimer

JCO Precis Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nationwide real-world practice pattern and clinical data of palbociclib in HR (+), HER2 (-) metastatic breast cancer patients in Korea (KCSG BR21-15).
Jieun Lee, Dae-Won Lee, Min Hwan Kim, Jee Hung Kim, Ju Won Kim, Han Jo Kim, Seul-Gi Kim, Ji-Yeon Kim, Gun Min Kim, Hyun Seon Kim, Seock-Ah Im

Breast· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DNA damage and Nuclear Anaplasia Induced by Trastuzumab Deruxtecan in Cancer Cells with Variable HER2 Expression and Homologous Recombination Deficiency Status.
So Hyeon Kim, Yoonjung Park, Ahrum Min, Hye Yeon Park, Yu-Jin Kim, Seongyeong Kim, Jin-Soo Kim, Seock-Ah Im

Cancer Res Treat· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer with residual invasive cancer after neoadjuvant chemotherapy (MIRINAE trial, KCSG-BR18-21).
Jieun Lee, Hee Kyung Ahn, Kyung-Hun Lee, Kyung Hae Jung, Yeon Hee Park, Sung Hoon Sim, Min Hwan Kim, Jee Hyun Kim, Jee Hung Kim, Seungtaek Lim, Han Jo Kim, Ji-Yeon Kim, Sung-Bae Kim, Gun Min Kim, Seock-Ah Im

BMC Cancer· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall Survival with Inavolisib in -Mutated Advanced Breast Cancer.
Komal L Jhaveri, Seock-Ah Im, Cristina Saura, Sibylle Loibl, Kevin Kalinsky

N Engl J Med· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence of germline pathogenic variants in unselected Korean patients with HER2-negative metastatic breast cancer: a nationwide prospective study (KCSG BR19-10).
Hee Kyung Ahn, Jee Hung Kim, Su-Jin Koh, Joohyuk Sohn, Myoung Joo Kang, Hee-Jun Kim, Jee Hyun Kim, Han Jo Kim, Jung Lim Lee, Ji-Yeon Kim, Seock-Ah Im

Lancet Reg Health West Pac· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MSN/STAT3 drives cancer stemness and chemoresistance via IL-6/LPAR1 ligand receptor complex in triple-negative breast cancer.
Cheng Hyun Lee, Soo Young Park, Jae Seok Lee, Da Sol Kim, Ha Yeon Kim, Seock-Ah Im

Breast Cancer Res· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cyclin dependent kinase 9 inhibitor induces transcription-replication conflicts and DNA damage accumulation in breast cancer.
Minyoung Lee, Kyung-Hun Lee, Ahrum Min, So Hyeon Kim, Sujin Ham, Youlim Noh, Yu-Jin Kim, Seock-Ah Im

Cancer Cell Int· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Establishment and characterization of 24 breast cancer cell lines and 3 breast cancer organoids reveals molecular heterogeneity and drug response variability in malignant pleural effusion-derived models.
Soon-Chan Kim, Ga-Hye Kim, Jae-Hyeon Park, Kyung-Hun Lee, Jiwon Koh, Tae-Yong Kim, Yu-Jin Kim, Seongyeong Kim, Seock-Ah Im

Breast Cancer Res· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2- Breast Cancer Treated With Endocrine Therapy With or Without Palbociclib: A Secondary PENELOPE-B Study Analysis.
Eric Hahnen, Jan Hauke, Karen Gelmon, Frederik Marmé, Corinna Ernst, Seock-Ah Im, Sung-Bae Kim, Toralf Reimer

JCO Precis Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elimusertib, a Novel ATR Inhibitor, Induces Anti-Tumor Effects through Replication Catastrophe in Breast Cancers.
Mudong Kim, Ahrum Min, Sohyeon Kim, Seongyeong Kim, Yu-Jin Kim, Jinyong Kim, Seock-Ah Im

Cancer Res Treat· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer.
Peter Schmid, Mafalda Oliveira, Joyce O'Shaughnessy, Massimo Cristofanilli, Stephanie L Graff, Seock-Ah Im

Ther Adv Med Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study.
Rebecca Dent, Javier Cortés, Yeon Hee Park, Eva Muñoz-Couselo, Sung-Bae Kim, Seock-Ah Im

Breast Cancer Res· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis